Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously. Catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway, with the intent of improving safety and efficacy of the two components. The conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes, releasing both bioactives within the cells of target tissues.